The goal of AlphaThera is to make antibody labeling as simple and consistent as possible, giving scientists confidence in their bioconjugation reactions.

AlphaThera was Co-founded by Dr. Andrew Tsourkas and Dr. James Hui in 2016. Dr. Andrew Tsourkas is a Professor of Bioengineering and Head of the Targeted Imaging, Therapeutics and Nanomedicine (TITAN) lab at the University of Pennsylvania.

James Hui joined the lab of Dr. Tsourkas, while he was an M.D./Ph.D. student at the University of Pennsylvania and he spearheaded the idea of using photoreactive antibody-binding domains to site-specifically label the heavy chain of Immunoglobulin G (IgG). Through these efforts, they developed the technology of LASIC (Light Assisted Site-specific Conjugation) and the family of reagents that are now known as oYo-Link®.

The oYo-Link products offer a next-gen bioconjugation platform to efficiently immobilize antibodies or label antibodies with various functional molecules, including dyes, biotins, DNA strands and more.

AlphaThera continues R&D in the Pennovation Lab space while also validating new applications for our oYo-Link technology, such as the recently launched oYo-Link Oligo conjugation product enabling customers to attach DNA strands to their antibodies for single-cell or subcellular analysis.

If you want more information about oYo-Link or a quote, do not hesitate to contact: